Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 15/20 | 0.58 |
| ▸ | BRD9 | Q9H8M2 | 5/20 | 0.50 |
| ▸ | CECR2 | Q9BXF3 | 4/20 | 0.48 |
| ▸ | TAF1 | P21675 | 4/20 | 0.47 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.47 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.45 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.45 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.45 |
| ▸ | EP300 | Q09472 | 1/20 | 0.45 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.45 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.45 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13329893 | 0.80 | BRD4 (0.59) | BRD4BRD9CECR2TAF1BRPF1 | |
| SCHEMBL22516602 | 0.79 | BRD4 (0.58) | BRD4BRD9CECR2TAF1BRPF1 | |
| SCHEMBL22600098 | 0.79 | BRD4 (0.58) | BRD4BRD9CECR2TAF1BRPF1 | |
| SCHEMBL24556455 | 0.77 | BRD4 (0.56) | BRD4BRD9CECR2TAF1BRPF1 | |
| SCHEMBL17748870 | 0.77 | BRD9 (0.57) | BRD4BRD9CECR2 | |
| SCHEMBL21445298 | 0.76 | BRD4 (0.55) | BRD4BRD9CECR2TAF1BRPF1 | |
| SCHEMBL19871750 | 0.76 | BRD4 (0.55) | BRD4BRD9CECR2TAF1BRPF1 | |
| SCHEMBL32691563 | 0.75 | BRD4 (0.48) | BRD4TRIM24BAZ2A | |
| SCHEMBL17748997 | 0.75 | BRD4 (0.57) | BRD4BRD9CECR2TAF1BRPF1 | |
| SCHEMBL17748894 | 0.73 | BRD4 (1.00) | BRD4BRD9CECR2TAF1BRPF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522600-B2 | Crystal form and salt form of bromine domain protein inhibitor and preparation method therefor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2026-01-13 | — | — | US | disclosed |
| CN-114929703-B | Crystal form and salt form of bromodomain protein inhibitor and preparation method thereof | 正大天晴药业集团股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-114401964-B | Compound with BRD4 inhibitory activity, preparation method and application thereof | 上海海和药物研究开发股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| US-20240150343-A1 | COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | HAIHE BIOPHARMA CO., LTD. (CN) | 2024-05-09 | — | — | US | disclosed |
| US-20240101551-A1 | CRYSTAL FORM AND SALT FORM OF BROMINE DOMAIN PROTEIN INHIBITOR AND PREPARATION METHOD THEREFOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-03-28 | — | — | US | disclosed |
| CN-117486861-A | Nitrogen-containing heterocyclic compound, preparation method and application thereof | 索智生物科技（浙江）有限公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-4234554-A2 | CRYSTALLINE SOLID FORMS OF A BET INHIBITOR | Incyte Corporation (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20150148342-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-05-28 | — | — | US | disclosed |
| US-8975417-B2 | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2015-03-10 | — | — | US | disclosed |
| US-20140349990-A1 | Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | disclosed |
| EP-2797918-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| WO-2014125408-A2 | SUBSTITUTED 1H-PYRROLOPYRIDINONE DERIVATIVES AS KINASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-08-21 | — | — | WO | disclosed |
| WO-2014125408-A2 | SUBSTITUTED 1H-PYRROLOPYRIDINONE DERIVATIVES AS KINASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-08-21 | — | — | WO | disclosed |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-06-12 | — | — | US | disclosed |
| WO-2013097601-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| CN-102372707-A | Synthetic method of 6-methyl-4-bromine-1,6-dihydropyrrole[2,3-c]pyridine-7-one | WUXI APPTEC CO LTD | 2012-03-14 | — | — | CN | disclosed |
| CN-102372707-A | Synthetic method of 6-methyl-4-bromine-1,6-dihydropyrrole[2,3-c]pyridine-7-one | WUXI APPTEC CO LTD | 2012-03-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150343-A1 | COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | BRD4, BICRA, BET1 | BRD4 1/4885BRD9 16/4885CECR2 2314/4885 |
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | BRD4, BRD1, BRD3 | BRD4 1/4885BRD9 10/4885CECR2 3296/4885 |
| US-20240101551-A1 | CRYSTAL FORM AND SALT FORM OF BROMINE DOMAIN PROTEIN INHIBITOR AND PREPARATION METHOD THEREFOR | BET1, BRD7, BRWD1 | BRD4 9/4885BRD9 21/4885CECR2 3561/4885 |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | BRD4 1/4885BRD9 14/4885CECR2 598/4885 |
| US-20140349990-A1 | Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease | PKD1, PKD2, REN | BRD4 652/4885BRD9 1003/4885CECR2 4343/4885 |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | BRD4 1/4885BRD9 14/4885CECR2 598/4885 |
| US-20150148342-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | BRD4 4/4885BRD9 8/4885CECR2 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.